Cite
The OVAREX study: Establishment of ex vivo ovarian cancer models to validate innovative therapies and to identify predictive biomarkers.
MLA
Thorel, Lucie, et al. “The OVAREX Study: Establishment of Ex Vivo Ovarian Cancer Models to Validate Innovative Therapies and to Identify Predictive Biomarkers.” BMC Cancer, vol. 24, no. 1, June 2024, pp. 1–9. EBSCOhost, https://doi.org/10.1186/s12885-024-12429-w.
APA
Thorel, L., Divoux, J., Lequesne, J., Babin, G., Morice, P.-M., Florent, R., Desmartin, G., Lecouflet, L., Marde Alagama, C., Leconte, A., Clarisse, B., Briand, M., Rouzier, R., Gaichies, L., Martin-Françoise, S., Le Brun, J.-F., Denoyelle, C., Vigneron, N., Jeanne, C., & Blanc-Fournier, C. (2024). The OVAREX study: Establishment of ex vivo ovarian cancer models to validate innovative therapies and to identify predictive biomarkers. BMC Cancer, 24(1), 1–9. https://doi.org/10.1186/s12885-024-12429-w
Chicago
Thorel, Lucie, Jordane Divoux, Justine Lequesne, Guillaume Babin, Pierre-Marie Morice, Romane Florent, Guillaume Desmartin, et al. 2024. “The OVAREX Study: Establishment of Ex Vivo Ovarian Cancer Models to Validate Innovative Therapies and to Identify Predictive Biomarkers.” BMC Cancer 24 (1): 1–9. doi:10.1186/s12885-024-12429-w.